Amupime500 mg/vial

Amupime 500 mg/vial is a fourth-generation cephalosporin antibiotic indicated for the treatment of moderate to severe bacterial infections caused by susceptible strains of microorganisms. Because of its broad-spectrum activity against both Gram-positive and Gram-negative bacteria, it is widely used in hospital settings for serious or complicated infections.

Cefepime is indicated for the following conditions:

• Pneumonia (moderate to severe): Caused by Streptococcus pneumoniae (including cases associated with concurrent bacteremia), Pseudomonas aeruginosa, Klebsiella pneumoniae, or Enterobacter species.
• Febrile Neutropenia: As empiric monotherapy for febrile neutropenic patients. In patients at high risk of severe infection—such as those with recent bone marrow transplantation, hypotension at presentation, an underlying hematologic malignancy, or severe/prolonged neutropenia—monotherapy may not be adequate, as supporting efficacy data are limited.
• Urinary Tract Infections (uncomplicated and complicated, including pyelonephritis): Caused by Escherichia coli or Klebsiella pneumoniae in severe infections, or by Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in mild to moderate infections, including cases with concurrent bacteremia.
• Uncomplicated Skin and Skin Structure Infections: Caused by Staphylococcus aureus (methicillin-susceptible strains only) or Streptococcus pyogenes.
• Complicated Intra-abdominal Infections: Used in combination with metronidazole for infections caused by Escherichia coli, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Enterobacter species, or Bacteroides fragilis.

Cefepime should be used only under the supervision of a registered physician after a confirmed or strongly suspected bacterial infection.

Amupime 500 mg/vial belongs to the therapeutic class of Fourth-generation cephalosporins. This class of beta-lactam antibiotics is valued for its broad spectrum of activity against both Gram-positive and Gram-negative bacteria, including many organisms resistant to earlier-generation cephalosporins.

Cefepime is a fourth-generation cephalosporin that exerts its effect through a bactericidal (bacteria-killing) mechanism, sharing the same fundamental mode of action as other beta-lactam antibiotics such as penicillins. It works by disrupting the synthesis of the peptidoglycan layer of the bacterial cell wall.

The peptidoglycan layer is essential for the structural integrity of the bacterial cell wall, particularly in Gram-positive organisms. The final cross-linking (transpeptidation) step in peptidoglycan synthesis is facilitated by enzymes known as penicillin-binding proteins (PBPs). By binding to and inhibiting these PBPs, cefepime prevents proper cell wall formation, leading to cell lysis and death of the bacterium.

A key advantage of cefepime is its enhanced stability against many beta-lactamase enzymes and its ability to penetrate the outer membrane of Gram-negative bacteria rapidly. This gives it a broader spectrum of activity than earlier-generation cephalosporins, covering many Gram-positive organisms as well as resistant Gram-negative pathogens such as Pseudomonas aeruginosa.

Cefepime may interact with certain medications, potentially increasing the risk of adverse effects. Care should be taken when it is co-administered with the following drug classes:

• Aminoglycoside antibiotics: Renal function should be carefully monitored when high doses of aminoglycosides are administered with cefepime, due to the increased potential for nephrotoxicity (kidney damage) and ototoxicity (hearing damage) associated with aminoglycosides.
• Potent diuretics (e.g., furosemide): Nephrotoxicity has been reported following the concomitant administration of cephalosporins with potent loop diuretics such as furosemide, so kidney function should be monitored during combined use.

Always inform your physician of all prescription medicines, over-the-counter drugs, and supplements you are taking before starting cefepime therapy.

Like all medications, Amupime 500 mg/vial may cause side effects, although not everyone experiences them. One of the most common side effects is gastrointestinal upset.

Patients may experience symptoms such as:

• Nausea
• Vomiting
• Diarrhea
• Abdominal pain

These gastrointestinal symptoms are usually mild and transient, though they can be bothersome for some individuals. Taking the medication with food, where appropriate, may help reduce these effects. Other reactions such as injection-site inflammation, rash, or headache may also occur. Any severe, persistent, or unusual symptoms should be reported to a physician promptly.

Pregnancy (Category B): There are no adequate and well-controlled studies of cefepime use in pregnant women. Because animal reproduction studies are not always predictive of the human response, this drug should be used during pregnancy only if clearly needed and under the guidance of a physician.

Lactation: Cefepime is excreted into human breast milk in very low concentrations (approximately 0.5 µg/mL). Caution should be exercised when cefepime is administered to a nursing mother.

To ensure safe and effective use, the following precautions should be observed during cefepime therapy:

• Appropriate use: Prescribing cefepime in the absence of a proven or strongly suspected bacterial infection—or a valid prophylactic indication—is unlikely to benefit the patient and increases the risk of drug-resistant bacteria.
• Superinfection: As with other antimicrobials, prolonged use may result in the overgrowth of non-susceptible microorganisms. Repeated evaluation of the patient's condition is essential.
• Prothrombin activity: Many cephalosporins, including cefepime, have been associated with a fall in prothrombin activity. Those at risk include patients with renal or hepatic impairment, poor nutritional status, or those on a protracted course of antimicrobial therapy. Prothrombin time should be monitored in at-risk patients.
• Gastrointestinal disease: Cefepime should be prescribed with caution in individuals with a history of gastrointestinal disease, particularly colitis.
• Arginine content: Arginine has been shown to alter glucose metabolism and transiently elevate serum potassium when administered at 33 times the amount provided by the maximum recommended human dose of cefepime. The effect of lower doses is not presently known.

Accidental overdosing has occurred when large doses were administered to patients with impaired renal function. Patients who receive an overdose should be carefully observed and given supportive treatment.

Symptoms of overdose may include:

• Encephalopathy (disturbance of consciousness including confusion, hallucinations, stupor, and coma)
• Myoclonus (involuntary muscle jerking)
• Seizures
• Neuromuscular excitability

In the presence of renal insufficiency, hemodialysis (not peritoneal dialysis) is recommended to help remove cefepime from the body.

• Do not use the medicine later than the date of expiry printed on the pack.
• Keep all medicines out of the reach of children.
• To be dispensed only on the prescription of a registered physician.

Pediatric Use (2 months up to 16 years): The maximum dose for pediatric patients should not exceed the recommended adult dose. For children weighing up to 40 kg, the usual dose for uncomplicated and complicated urinary tract infections (including pyelonephritis), uncomplicated skin and skin structure infections, and pneumonia is 50 mg/kg/dose every 12 hours. For febrile neutropenic patients, the dose is 50 mg/kg/dose every 8 hours, for durations as recommended for adults.

Geriatric Use: Serious adverse events have occurred in elderly patients with renal insufficiency who received unadjusted doses of cefepime, including life-threatening or fatal encephalopathy, myoclonus, and seizures. Since cefepime is substantially excreted by the kidneys, and elderly patients are more likely to have decreased renal function, dose selection should be made with care and renal function should be monitored.

Impaired Hepatic Function: No dose adjustment is necessary in patients with impaired liver function.

Impaired Renal Function: In patients with impaired renal function (creatinine clearance < 60 mL/min), the dose should be adjusted to compensate for the slower rate of renal elimination.

Proper reconstitution ensures the correct concentration and compatibility of cefepime for administration. For intravenous use, the resulting solution should be injected directly into the vein over a period of three to five minutes, or injected into the tubing of an administration set while the patient is receiving a compatible IV fluid.

Intravenous compatibility: Cefepime is compatible with Sterile Water for Injection. It is also compatible, at concentrations between 1 mg/mL and 40 mg/mL, with the following IV infusion fluids: 0.9% Sodium Chloride Injection, 5% and 10% Dextrose Injection, M/6 Sodium Lactate Injection, 5% Dextrose and 0.9% Sodium Chloride Injection, and Lactated Ringer's and 5% Dextrose Injection.

Intramuscular compatibility: Cefepime is compatible with the following diluents: Sterile Water for Injection, 0.9% Sodium Chloride Injection, 5% Dextrose Injection, Sterile Bacteriostatic Water for Injection with Parabens or Benzyl Alcohol, or 0.5%/1% Lidocaine Hydrochloride.

The following table outlines the recommended volumes for reconstituting each vial size:

Fourth generation Cephalosporins

Cephalosporins are bactericidal and have the same mode of action as other beta-lactam antibiotics (such as penicillins). Cephalosporins disrupt the synthesis of the peptidoglycan layer of bacterial cell walls. The peptidoglycan layer is important for cell wall structural integrity, especially in Gram-positive organisms. The final transpeptidation step in the synthesis of the peptidoglycan is facilitated by transpeptidases known as penicillin binding proteins (PBPs).

Pregnancy Category B. There are, however, no adequate and well-controlled studies of cefepime use in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. Cefepime is excreted in human breast milk in very low concentrations (0.5 pg/ml). Caution should be exercised when cefepime is administered to a nursing woman.

Pediatric Use (2 months up to 16 years): The maximum dose for pediatric patients should not exceed the recommended adult dose. The usual recommended dosage in pediatric patients up to 40 kg in weight for uncomplicated and complicated urinary tract infections (including pyelonephritis), uncomplicated skin and skin structure infections, and pneumonia is 50 mg/kg/dose, administered every 12 hours (50 mg/kg/dose, every 8 hours for febrile neutropenic patients), for durations as given above.Geriatric Use: Serious adverse events have occurred in geriatric patients with renal insufficiency given unadjusted doses of cefepime, including life-threatening or fatal occurrences of the following: encephalopathy, myoclonus, and seizures. This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and renal function should be monitored. Impaired Hepatic Function: No adjustment is necessary for patients with impaired hepatic function.Impaired Renal Function: In patients with impaired renal function (creatinine clearance<60 ml/min), the dose of Cefepime should be adjusted to compensate for the slower rate of renal elimination.